Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial
Andrew Hastie, Tanya Clarke, Sophie Germain, Thierry Ollinger, Patricia Lese, Vinay Gupta · 2024
Read Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial by Andrew Hastie, Tanya Clarke, Sophie Germain, Thierry Ollinger, Patricia Lese, Vinay Gupta (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11658966.txt.
Description
Andrew Hastie and co-authors present a 2024 trial report on a vaccine against the H7N9 bird flu strain. The virus could spark a pandemic, so a ready vaccine matters. The trial tested an H7N9 vaccine boosted with the AS03 adjuvant in two age bands: adults 18 to 64 and those 65 and older.
Over 400 volunteers in each band received one of six dose and adjuvant mixes or a placebo. Blood tests 21 days after the second dose measured the immune response. The vaccines did raise antibody responses, but not enough to meet the regulator's criteria. One adjuvant blend trended stronger, above all in older adults. Sore arms and fatigue were more common with the real vaccines. No serious side effects were tied to them.
Catalog record
| CREATOR | Andrew Hastie, Tanya Clarke, Sophie Germain, Thierry Ollinger, Patricia Lese, Vinay Gupta |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |